Rowan T. Chlebowski

May 13, 2024 | acsjournals.onlinelibrary.wiley.com | Rowan T. Chlebowski |Aaron K. Aragaki |Kathy Pan |Michael Simon

CONFLICT OF INTEREST STATEMENT Rowan T. Chlebowski reports receiving personal fees from Novartis, AstraZeneca, Pfizer, and UpToDate during the conduct of the study. Joanne E. Mortimer has been a consultant for AstraZeneca and Novartis. Andrew M. Kaunitz has received grants from Bayer. Robert A. Wild has received grants from Boston Heart Diagnostics and Quest Medical and holds intellectual property with Partners Health Care. The other authors declare no conflicts of interest.

Mar 21, 2023 | jamanetwork.com | Rowan T. Chlebowski |Aaron K. Aragaki

[Skip to Navigation] March 21, 2023 JAMA. 2023;329(11):942. doi:10.1001/jama.2023.0186 Full Text To the Editor The WHI placebo-controlled trial1 involved 10 739 postmenopausal women with prior hysterectomy, and breast cancer incidence was the primary safety outcome.